Cosmos Health Inc (COSM)

Over the past year, Cosmos Health's stock has experienced a significant change of -37.19%, with a 52-week trading range between $0.2801 and $1.3200. Key events impacting the stock price include securing a financing facility, reporting Q2 and Q3 results, filing to sell shares, purchasing Ethereum, regaining compliance with Nasdaq's listing rule, reporting record Q3 results, a stock tumble, CEO shareholding increases, another record quarter, Zacks Small-Cap Research initiating coverage, and Cosmofarm's operational growth and infrastructure expansion. CEO Grigorios Siokas also acquired approximately 1,000,000 new shares through a series of debt exchange agreements.

Specific information regarding the demand seasonality for Cosmos Health, Inc.'s products and services is not publicly available in the provided search results. While the company operates in the pharmaceutical and nutraceutical sectors, which may have general seasonal trends, no company-specific data on demand seasonality was found.

Cosmos Health, Inc. is a diversified, vertically integrated global healthcare group involved in the wholesale of pharmaceutical products throughout Europe and the nutraceuticals sector. The company's major products include prescription medications, over-the-counter drugs, medical devices, food supplements, nutraceuticals, and cosmetics. Cosmos Health also focuses on research and development of novel patented nutraceuticals, specialized root extracts, proprietary complex generics, and innovative OTC products, supported by its Cloudscreen AI-enabled drug repurposing platform. Cosmos Health has also expanded into telehealth services through its acquisition of ZipDoctor, Inc.

Cosmos Health, Inc. has a global distribution platform with operations in Greece, the United Kingdom, Croatia, Bulgaria, the United Arab Emirates, and Cyprus. The company maintains offices and distribution centers in Chicago, USA; Athens and Thessaloniki, Greece; and Harlow, UK. Its cross-border pharmaceutical business serves wholesale pharmaceutical distributors and independent retail pharmacies across the European Union.

Cosmos Health's brand reputation has been mixed. The company received a "Sell" consensus rating from analysts, and its MarketRank™ score indicated underperformance compared to other companies in the medical sector. However, Zacks Small-Cap Research initiated coverage with a positive valuation, highlighting the company's diversified revenue, integrated operations, technology initiatives, U.S. expansion, and improving financial performance. The company also announced continued operational growth at its Cosmofarm subsidiary in Greece, and the CEO's consistent buying of company shares signals confidence in the company's future.

Cosmos Health Inc. has 24 institutional owners and shareholders holding a total of 1,219,929 shares. Major institutional owners include BlackRock, Inc., Vanguard Group Inc, Citadel Advisors Llc, Geode Capital Management, Llc, VEXMX - Vanguard Extended Market Index Fund Investor Shares, Renaissance Technologies Llc, XTX Topco Ltd, State Street Corp, Northern Trust Corp, and Susquehanna International Group, Llp. Insiders hold 25.10% of the company's stock, while institutions hold 12.61%. CEO Grigorios Siokas is a significant individual owner, having substantially increased his shareholding in 2025 and early 2026, bringing his total ownership to 6,459,985 shares by December 2025.